When Patents Are Not Enough: Data Exclusivity for Follow-On Biologics

James Bessen, Michael James Meurer, Patent Failure: How Judges, Bureaucrats, and Lawyers Put Innovators at Risk ,(2008)

Janet Woodcock, Joseph Griffin, Rachel Behrman, Barry Cherney, Terrie Crescenzi, Blair Fraser, Dena Hixon, Christopher Joneckis, Steven Kozlowski, Amy Rosenberg, Lewis Schrager, Emily Shacter, Robert Temple, Keith Webber, Helen Winkle, The FDA's assessment of follow-on protein products: a historical perspective. Nature Reviews Drug Discovery. ,vol. 6, pp. 437- 442 ,(2007) , 10.1038/NRD2307

Joseph A. DiMasi, Henry G. Grabowski, The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics. ,vol. 28, pp. 469- 479 ,(2007) , 10.1002/MDE.1360

John E. Calfee, Elizabeth DuPré, The Emerging Market Dynamics Of Targeted Therapeutics Health Affairs. ,vol. 25, pp. 1302- 1308 ,(2006) , 10.1377/HLTHAFF.25.5.1302

Laurent Sailler, Rituximab Off Label Use for Difficult-To-Treat Auto-Immune Diseases: Reappraisal of Benefits and Risks Clinical Reviews in Allergy & Immunology. ,vol. 34, pp. 103- 110 ,(2008) , 10.1007/S12016-007-8020-7

Henry F. McFarland, The B cell--old player, new position on the team. The New England Journal of Medicine. ,vol. 358, pp. 664- 665 ,(2008) , 10.1056/NEJMP0708143

Ryan P. Million, Therapeutic area crossroads: anti-angiogenesis Nature Reviews Drug Discovery. ,vol. 7, pp. 115- 116 ,(2008) , 10.1038/NRD2507

Henry Grabowski, Follow-on biologics: data exclusivity and the balance between innovation and competition Nature Reviews Drug Discovery. ,vol. 7, pp. 479- 488 ,(2008) , 10.1038/NRD2532

Joseph A DiMasi, Ronald W Hansen, Henry G Grabowski, The price of innovation: new estimates of drug development costs Journal of Health Economics. ,vol. 22, pp. 151- 185 ,(2003) , 10.1016/S0167-6296(02)00126-1

Fortunato Ciardiello, Giampaolo Tortora, EGFR Antagonists in Cancer Treatment The New England Journal of Medicine. ,vol. 358, pp. 1160- 1174 ,(2008) , 10.1056/NEJMRA0707704